Outset Medical Inc (OM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $70.39M
Last updated: Nov 17, 2026 at 11:05 AM ET
Outset Medical Inc (OM) Stock Forecast
Analysts expect Outset Medical (OM) to earn -$2.99 per share in the fiscal year ending Dec 31, 2026, on revenue of $127.40M. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 66.7% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9.8%.
- Fiscal year ending Dec 31, 2026
- -$2.99
- EPS consensus, revenue $127.40M
- Fiscal year ending Dec 31, 2027
- -$2.32
- EPS consensus, revenue $139.87M
- Next report
- Jan 11, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.99 | -$3.06 to -$2.91 | 3 | $127.40M | $126.80M to $127.90M | 3 |
| Dec 31, 2027 | -$2.32 | -$2.50 to -$2.19 | 3 | $139.87M | $139.10M to $141.20M | 3 |
Quarterly Estimates
The EPS consensus falls from -$0.68 for the quarter ending Dec 31, 2026 to -$0.70 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.68 | -$0.72 to -$0.63 | 6 | $35.43M | $33.03M to $36.85M | 6 |
| Mar 31, 2027 | -$0.70 | -$0.82 to -$0.58 | 2 | $31.10M | $29.80M to $32.40M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.09.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.99 | -$3.08 | -$3.08 | -$3.09 | -$3.09 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.32 | -$2.29 | -$2.29 | -$2.29 | -$2.29 | N/A |
| Quarter ending Mar 31, 2027 | -$0.70 | -$0.81 | -$0.81 | -$0.81 | -$0.81 | N/A |
Frequently Asked Questions About OM
What is the OM stock forecast?
Consensus analyst estimates put Outset Medical's EPS at -$2.99 for the fiscal year ending Dec 31, 2026, on revenue of $127.40M. The consensus rating from 3 analysts is Buy.
How do analysts rate OM stock?
Of 3 analysts covering Outset Medical, 0 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.99, with estimates from -$3.06 to -$2.91 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.32, with estimates from -$2.50 to -$2.19 from 3 analysts.
What revenue do analysts expect from Outset Medical next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $127.40M, with estimates from $126.80M to $127.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $139.87M, with estimates from $139.10M to $141.20M.
How many analysts cover OM?
3 analysts rate Outset Medical stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OM pages: Overview, Earnings, Forecast, Financials, Competitors